Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Patterns of Medication Utilization and Migraine Frequency in Adults Using Rimegepant for Both Preventive and Acute Treatment for Migraine: Results From a 52-Week, Open-Label Extension Study

              Author:Hutchinson, Susan   Mullin, Kathleen   Pavlovic, Jelena   Lipton, Richard   Jensen, Christopher   Thiry, Alexandra   Kamen, Lisa   Croop, Robert   

              Session Name:P9: Headache: The Gepant Pipeline  

              Topic:Headache  

              Program Number:P9.006  

              Author Institution:Orange County Migraine & Headache Center, Irvine, CA  New England Institute for Neurology and Headache, Stamford, CT  Albert Einstein College of Medicine, Bronx, NY  Biohaven Pharmaceuticals, New Haven, CT  

              Rimegepant for the Acute and Preventive Treatment of Migraine in Women: Results From 4 Randomized, Placebo-Controlled Clinical Trials

              Author:Hutchinson, Susan   Pavlovic, Jelena   Ailani, Jessica   Mullin, Kathleen   Croop, Robert   Thiry, Alexandra   Morris, Beth   Kamen, Lisa   Abbott, Chandra   

              Session Name:P9: Headache: The Gepant Pipeline  

              Topic:Headache  

              Program Number:P9.007  

              Author Institution:Orange County Migraine & Headache Center, Irvine, CA  Albert Einstein College of Medicine, Bronx, NY  Medstar Georgetown Neurology, McLean, VA  New England Institute for Neurology and Headache, Stamford, CT  Biohaven Pharmaceuticals, Wynnewood, PA  Biohaven Pharmaceuticals, New Haven, CT  Biohaven Pharmaceuticals, Inc., New Haven, CT  

              Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine in Black and African American Adults: Results From 3 Randomized, Placebo-Controlled Clinical Trials

              Author:Charleston, Larry   Armand, Cynthia   Helveston, Wendell   Monteith, Teshamae   O'Brien, Hope   Croop, Robert   Thiry, Alexandra   Morris, Beth   Forshaw, Micaela   Abbott, Chandra   

              Session Name:P9: Headache: The Gepant Pipeline  

              Topic:Headache  

              Program Number:P9.009  

              Author Institution:Michigan State University College of Human Medicine, East Lansing, MI  Montefiore Medical Headache Center, Bronx, NY  Hattiesburg Clinic, Hattiesburg, MS  University of Miami, Miami, FL  Headache Center of Hope, Cincinnati, OH  Biohaven Pharmaceuticals, Wynnewood, PA  Biohaven Pharmaceuticals, New Haven, CT  

              Effects of Rimegepant 75 mg on Monthly Migraine Days: a 52-Week, Open-Label Extension Study

              Author:Croop, Robert   Ailani, Jessica   Kudrow, David   Smith, Timothy   Lipton, Richard   Thiry, Alexandra   Jensen, Christopher   Kamen, Lisa   

              Session Name:P10: Headache: Towards Precision Medicine 1  

              Topic:Headache  

              Program Number:P10.010  

              Author Institution:Biohaven Pharmaceuticals , Wynnewood, PA  Medstar Georgetown Neurology, McLean, VA  David Kudrow MD, Los Angeles, CA  Study Metrix Research, Saint Peters, MO  Albert Einstein College of Medicine, Bronx, NY  Biohaven Pharmaceuticals, New Haven, CT  

              Medication Preference, Satisfaction, and Clinical Improvement Among Adults Receiving Long-Term Treatment With Rimegepant for Migraine

              Author:Mullin, Kathleen   Pavlovic, Jelena   Hutchinson, Susan   Lipton, Richard   Jensen, Christopher   Thiry, Alexandra   Kamen, Lisa   Croop, Robert   

              Session Name:P10: Headache: Towards Precision Medicine 1  

              Topic:Headache  

              Program Number:P10.011  

              Author Institution:New England Institute for Neurology and Headache, Stamford, CT  Albert Einstein College of Medicine, Bronx, NY  Orange County Migraine & Headache Center, Irvine, CA  Biohaven Pharmaceuticals, New Haven, CT  Biohaven Pharmaceuticals, Wynnewood, PA